Related references
Note: Only part of the references are listed.Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients
Michele Correale et al.
HEART FAILURE REVIEWS (2023)
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
Detmar Kolijn et al.
CARDIOVASCULAR RESEARCH (2021)
Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells
Laween Uthman et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
Zhaoyang Hu et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves
Kenichi Katsurada et al.
CIRCULATION-HEART FAILURE (2021)
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Agata Winiarska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study
B. Gaborit et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up
Celestino Sardu et al.
FRONTIERS IN PHARMACOLOGY (2021)
Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
Nunzia D'Onofrio et al.
MOLECULAR METABOLISM (2021)
The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
Ziyu Meng et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
The changing landscape of atherosclerosis
Peter Libby
NATURE (2021)
Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy
Shiva Borzouei et al.
HUMAN IMMUNOLOGY (2021)
Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways
Nami Lee et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2021)
Metformin Therapy Effects on the Expression of Sodium-Glucose Cotransporter 2, Leptin, and SIRT6 Levels in Pericoronary Fat Excised from Pre-Diabetic Patients with Acute Myocardial Infarction
Celestino Sardu et al.
BIOMEDICINES (2021)
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
Yihai Liu et al.
JOURNAL OF INFLAMMATION RESEARCH (2021)
Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence
Sonia Khemais-Benkhiat et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Association between serum levels of Klotho and inflammatory cytokines in cardiovascular disease: a case-control study
Ernesto Martin-Nunez et al.
AGING-US (2020)
Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
Sin-Hee Park et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
Nikole J. Byrne et al.
CIRCULATION-HEART FAILURE (2020)
Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Celestino Sardu et al.
CURRENT PHARMACEUTICAL DESIGN (2020)
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors JACC State-of-the-Art Review
Thomas A. Zelniker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice
Xiaodong Sun et al.
DIABETES (2020)
Effects of soy isoflavones on serum systemic and vascular inflammation markers and oxidative stress in peritoneal dialysis patients: A randomized controlled trial
Zahra Yari et al.
PHYTOTHERAPY RESEARCH (2020)
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies
Afnan S. Alshnbari et al.
DIABETES THERAPY (2020)
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martin R. Cowie et al.
NATURE REVIEWS CARDIOLOGY (2020)
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation
Chintan N. Koyani et al.
PHARMACOLOGICAL RESEARCH (2020)
Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis
Yingxiu Kang et al.
VASCULAR PHARMACOLOGY (2020)
Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice
Qing-Qing Zhang et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2020)
Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells
Yanli Guo et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
Arief Rahadian et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
George Vasquez-Rios et al.
INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE (2020)
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
Seul-Gee Lee et al.
KOREAN CIRCULATION JOURNAL (2020)
Psychosocial Stress and C-Reactive Protein From Mid-Adolescence to Young Adulthood
Jessica J. Chiang et al.
HEALTH PSYCHOLOGY (2019)
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Magnus Back et al.
NATURE REVIEWS CARDIOLOGY (2019)
Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study
Eu Jeong Ku et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Glucose Metabolism in Cardiac Hypertrophy and Heart Failure
Diem H. Tran et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
PECAM-1 Stabilizes Blood-Brain Barrier Integrity and Favors Paracellular T-Cell Diapedesis Across the Blood-Brain Barrier During Neuroinflammation
Isabella Wimmer et al.
FRONTIERS IN IMMUNOLOGY (2019)
IL-1 family cytokines in cardiovascular disease
Susanne Pfeiler et al.
CYTOKINE (2019)
Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
Liang Xu et al.
BMJ OPEN DIABETES RESEARCH & CARE (2019)
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats
Hiroto Oshima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
Ven G. Lim et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2019)
Metabolic Profiling of the Diabetic Heart: Toward a Richer Picture
Alice P. Sowton et al.
FRONTIERS IN PHYSIOLOGY (2019)
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
Chenke Xu et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Canagliflozin inhibits interleukin-1 beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Sarah J. Mancini et al.
SCIENTIFIC REPORTS (2018)
Th17 and Treg lymphocytes in obesity and Type 2 diabetic patients
Mei Wang et al.
CLINICAL IMMUNOLOGY (2018)
A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition
Yasutaka Miyachi et al.
SCIENTIFIC REPORTS (2018)
Cholesterol, CCR2, and monocyte phenotypes in atherosclerosis
Matthias Nahrendorf et al.
EUROPEAN HEART JOURNAL (2017)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
Yusuke Nakatsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Soluble Vascular Cell Adhesion Molecules May be Protective of Future Cardiovascular Disease Risk: Findings from the PREVEND Prospective Cohort Study
Setor K. Kunutsor et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Interleukin-6 Trans-Signaling and Ischemic Vascular Disease: The Important Role of Soluble gp130
Mario Luca Morieri et al.
MEDIATORS OF INFLAMMATION (2017)
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Liang Xu et al.
EBIOMEDICINE (2017)
Interleukin-32 in chronic inflammatory conditions is associated with a higher risk of cardiovascular diseases
Michelle S. M. A. Damen et al.
ATHEROSCLEROSIS (2017)
Circulating Levels of Interleukin 1-Receptor Antagonist and Risk of Cardiovascular Disease Meta-Analysis of Six Population-Based Cohorts
Christian Herder et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Diagnostic approaches for diabetic cardiomyopathy
A. Lorenzo-Almoros et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease
Jose J. Fuster et al.
CIRCULATION RESEARCH (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Interleukin-18 gene polymorphism and risk of CVD in older patients with type 2 diabetes mellitus
Monika Buraczynska et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Aortic VCAM-1: an early marker of vascular inflammation in collagen-induced arthritis
Anne Denys et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice
Weiling Leng et al.
MEDIATORS OF INFLAMMATION (2016)
Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis
Jiayun Shen et al.
TRANSLATIONAL RESEARCH (2016)
Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction
Constantijn Franssen et al.
JACC-HEART FAILURE (2016)
Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse
Hotimah Masdan Salim et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2016)
Mechanisms of Myeloid Cell Modulation of Atherosclerosis
Filip K. Swirski et al.
MICROBIOLOGY SPECTRUM (2016)
Effect of 12-O-tetradecanoylphorbol-13-acetate-induced psoriasis-like skin lesions on systemic inflammation and atherosclerosis in hypercholesterolaemic apolipoprotein E deficient mice
Marie Madsen et al.
BMC DERMATOLOGY (2016)
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Yun-Hee Youm et al.
NATURE MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
IMMUNOLOGY Neutrophil-macrophage communication in inflammation and atherosclerosis
Matthias Nahrendorf et al.
SCIENCE (2015)
Epigenetic Changes in Bone Marrow Progenitor Cells Influence the Inflammatory Phenotype and Alter Wound Healing in Type 2 Diabetes
Katherine A. Gallagher et al.
DIABETES (2015)
Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
Michishige Terasaki et al.
PLOS ONE (2015)
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Michael A. Nauck
DRUG DESIGN DEVELOPMENT AND THERAPY (2014)
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
F. J. Lavalle-Gonzalez et al.
DIABETOLOGIA (2013)
TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis
Clemens Duerrschmid et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure
Filip K. Swirski et al.
SCIENCE (2013)
Supra-additive expression of interleukin-6, interleukin-8 and basic fibroblast growth factor in vascular smooth muscle cells following coinfection with Chlamydia pneumoniae and cytomegalovirus as a novel link between infection and atherosclerosis
Dirk Prochnau et al.
CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY (2012)
PKCδ signalling regulates SR-A and CD36 expression and foam cell formation
Chin-Sheng Lin et al.
CARDIOVASCULAR RESEARCH (2012)
The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications
Chun Zeng et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
PECAM-1 is a critical mediator of atherosclerosis
Hazel Y. Stevens et al.
DISEASE MODELS & MECHANISMS (2008)
Macrophage polarization in bacterial infections
Marie Benoit et al.
JOURNAL OF IMMUNOLOGY (2008)
Monocytes from type 2 diabetic patients have a pro-inflammatory profile -: 1,25-Dihydroxyvitamin D3 works as anti-inflammatory
Annapaula Giulietti et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
The immune response in atherosclerosis: a double-edged sword
Goran K. Hansson et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes
S Devaraj et al.
DIABETES (2006)
Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease
GK Hansson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
IS Wood et al.
BRITISH JOURNAL OF NUTRITION (2003)
Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway
D Schulman et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2002)
Share Paper
